Erleada and Hydrochlorothiazide and olmesartan
Determining the interaction of Erleada and Hydrochlorothiazide and olmesartan and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with apalutamide may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4, 2C9, 2C19, breast cancer resistance protein (BCRP), uridine diphosphate glucuronosyltransferase (UGT), organic anion transporting polypeptide 1B1 (OATP1B1), and/or P-glycoprotein (P-gp) efflux transporter. The proposed mechanism involves accelerated clearance via these routes due to apalutamide-mediated induction. The resulting plasma concentrations will depend on the sensitivity of the affected drugs to these isoenzymes. MANAGEMENT: Caution is advised when apalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, 2C9, 2C19, BCRP, UGT, OATP1B1, and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever apalutamide is added to or withdrawn from therapy. References "Product Information. Erleada (apalutamide)." Janssen Biotech, Inc., Horsham, PA, PA. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Professional:MONITOR: Coadministration with apalutamide may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4, 2C9, 2C19, breast cancer resistance protein (BCRP), uridine diphosphate glucuronosyltransferase (UGT), organic anion transporting polypeptide 1B1 (OATP1B1), and/or P-glycoprotein (P-gp) efflux transporter. The proposed mechanism involves accelerated clearance via these routes due to apalutamide-mediated induction. The resulting plasma concentrations will depend on the sensitivity of the affected drugs to these isoenzymes.
MANAGEMENT: Caution is advised when apalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, 2C9, 2C19, BCRP, UGT, OATP1B1, and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever apalutamide is added to or withdrawn from therapy.
- "Product Information. Erleada (apalutamide)." Janssen Biotech, Inc., Horsham, PA, PA.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: hydrochlorothiazide / olmesartan
Brand name: Benicar HCT
Synonyms: Olmesartan and Hydrochlorothiazide
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Erleada-Hydrochlorothiazide and propranolol
- Erleada-Hydrochlorothiazide and quinapril
- Erleada-Hydrochlorothiazide and spironolactone
- Erleada-Hydrochlorothiazide and telmisartan
- Erleada-Hydrochlorothiazide and triamterene
- Erleada-Hydrochlorothiazide and valsartan
- Hydrochlorothiazide and olmesartan-Erlotinib
- Hydrochlorothiazide and olmesartan-Erlotinib Tablets
- Hydrochlorothiazide and olmesartan-Errin
- Hydrochlorothiazide and olmesartan-Ertapenem
- Hydrochlorothiazide and olmesartan-Ertapenem Injection
- Hydrochlorothiazide and olmesartan-Ertapenem Sodium